100 Participants Needed

PARP Inhibitors for Ovarian Cancer

(4PDQ Trial)

Age: Any Age
Sex: Female
Trial Phase: Academic
Sponsor: University of Saskatchewan
Must be taking: PARP inhibitors
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Breakthrough TherapyThis drug has been fast-tracked for approval by the FDA given its high promise

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What data supports the effectiveness of the drug Niraparib for ovarian cancer?

Niraparib has been shown to increase the time patients live without their cancer getting worse (progression-free survival) in those with recurrent ovarian cancer after platinum-based chemotherapy, regardless of BRCA mutation status. It is also used as maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer, showing clinical activity in these cases.12345

Is niraparib safe for humans?

Niraparib, a treatment for ovarian cancer, has been studied for safety, showing that most patients experience some side effects, with serious ones like low blood cell counts and high blood pressure in some cases. Dose adjustments are often needed to manage these side effects, and there is a small risk of developing blood disorders like leukemia.678910

How is the drug Niraparib unique in treating ovarian cancer?

Niraparib is unique because it is an oral PARP inhibitor that can be used as maintenance therapy for ovarian cancer patients regardless of their BRCA mutation status, unlike other treatments that often require specific genetic markers. It is also notable for its use in patients who have responded to platinum-based chemotherapy, offering a new option for those with recurrent or newly diagnosed ovarian cancer.1231112

What is the purpose of this trial?

Patients with ovarian cancer with defective DNA repair mechanisms derive substantial benefit from PARP inhibitor (PARPi) maintenance therapy. Both niraparib and olaparib are effective inhibitors of PARP, which exploit already defective DNA repair mechanisms (e.g., via BRCA mutations), particularly those with homologous recombination deficiency (HRD). These two PARPis have notably different toxicity profiles, with niraparib showing many more severe side effects. In this Ovarian Cancer Canada funded study, we will implement perform HRD testing for ovarian cancer patients in Saskatchewan with response to platinum-based chemotherapy. This information will provide personalized and precision estimates about the amount of benefit that can be expected from taking a PARPi. We will evaluate both treatment outcomes and quality of life in a real-world study setting, to inform future decision-making regarding efficacy, quality of life and cost-effectiveness of PARPi therapy, specifically for niraparib.We hypothesize that for patients who are homologous recombinant proficient (HRP), the median 32.7-month incremental benefit (in delaying cancer progression) from taking a PARPi (niraparib is the only PARPi approved in this setting) will not be seen as being value-add when balanced by the decreased quality of life that accompanies the first 6-12 weeks of therapy. We also hypothesize that for women who are HRP, that PARPi therapy will not be cost-efficient.

Eligibility Criteria

This trial is for ovarian cancer patients in Saskatchewan who've responded to platinum-based chemotherapy and will undergo HRD testing. It's designed to help those with defective DNA repair mechanisms decide if PARPi therapy, specifically niraparib, is beneficial considering its impact on quality of life.

Inclusion Criteria

Able to provide oral consent and complete questionnaires in English as per study protocol
I have advanced ovarian cancer.

Exclusion Criteria

I refuse to have HRD testing.
I cannot receive maintenance PARPi therapy.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

HRD Testing

HRD testing is performed for ovarian cancer patients to determine eligibility for PARPi therapy

2 weeks

Treatment

Participants receive PARPi therapy, with a focus on evaluating treatment outcomes and quality of life

6-12 weeks

Follow-up

Participants are monitored for safety, effectiveness, and quality of life after treatment

6 months

Treatment Details

Interventions

  • Niraparib
Trial Overview The study tests the effectiveness of a decision aid for using PARP inhibitors (PARPi) like niraparib or olaparib in ovarian cancer patients with homologous recombination deficiency (HRD). It aims to balance treatment benefits against side effects and decreased quality of life during initial weeks.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: HRD TestedExperimental Treatment1 Intervention
HRP patients are given a decision aid, while HRD patients are not given a decision.

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Saskatchewan

Lead Sponsor

Trials
261
Recruited
156,000+

Findings from Research

Niraparib is the first PARP inhibitor approved for ovarian cancer treatment in patients without BRCA mutations, showing good tolerability and manageable hematologic side effects, especially with new dose modification guidelines.
Current research is exploring niraparib's effectiveness as a maintenance therapy after platinum-based chemotherapy and in recurrent high-grade serous ovarian cancer, highlighting the need for better biomarkers to identify which patients will benefit most from this treatment.
Niraparib for the treatment of ovarian cancer.Essel, KG., Moore, KN.[2019]
In a real-world study of 22 ovarian cancer patients treated with niraparib at a dose of 200 mg/day, the objective response rate was 33.3%, indicating promising efficacy, especially in patients with homologous recombination deficiency (HRD).
The most common adverse events included nausea, thrombocytopenia, and anemia, with severe thrombocytopenia managed through dose adjustments, suggesting that niraparib can be tolerated with appropriate monitoring and management.
The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China.Ni, J., Cheng, X., Zhao, Q., et al.[2021]
In a phase 3 trial involving 553 patients with platinum-sensitive, recurrent ovarian cancer, niraparib significantly improved progression-free survival compared to placebo, with median durations of 21.0 months versus 5.5 months for patients with gBRCA mutations, and 12.9 months versus 3.8 months for those with homologous recombination deficiency.
While niraparib was effective, it was associated with moderate bone marrow toxicity, with common grade 3 or 4 adverse events including thrombocytopenia (33.8%), anemia (25.3%), and neutropenia (19.6%), which were managed through dose adjustments.
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.Mirza, MR., Monk, BJ., Herrstedt, J., et al.[2022]

References

Niraparib for the treatment of ovarian cancer. [2019]
The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China. [2021]
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. [2022]
Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial☆. [2021]
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. [2019]
Safety and dose modification for patients receiving niraparib. [2021]
Niraparib and Advanced Ovarian Cancer: A Beacon in the Non-BRCA Mutated Setting. [2023]
Safety and management of niraparib monotherapy in ovarian cancer clinical trials. [2023]
The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities. [2019]
The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer. [2019]
11.United Statespubmed.ncbi.nlm.nih.gov
Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial. [2021]
12.United Statespubmed.ncbi.nlm.nih.gov
Identifying the need to refine the potential patient risk factors for niraparib-induced thrombocytopenia. [2019]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security